Yesterday, May 25, 2016, 98 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $88.32 to $137,937,966.40.

Highlighted Stocks Traded by Insiders:

Summit Materials (SUM) - FREE Research Report

Brady Michael John, who is Officer at Summit Materials, sold 35,228 shares at $21.85 on May 25, 2016. Following this transaction, the Officer owned 0 shares meaning that the stake was reduced by 100% with the 35,228-share transaction.

The shares most recently traded at $22.00, up $0.15, or 0.68% since the insider transaction. Historical insider transactions for Summit Materials go as follows:

  • 4-Week # shares bought: 77,700
  • 12-Week # shares bought: 77,700
  • 24-Week # shares bought: 77,700

The average volume for Summit Materials has been 898,700 shares per day over the past 30 days. Summit Materials has a market cap of $2.6 billion and is part of the industrial goods sector and materials & construction industry. Shares are up 12.33% year-to-date as of the close of trading on Wednesday.

Summit Materials, Inc., through its subsidiaries, produces and sells construction materials and related downstream products. The company has a P/E ratio of 32.8. Currently, there are 7 analysts who rate Summit Materials a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on SUM - FREE

TheStreet Quant Ratings

rates Summit Materials as a

sell

. The company's weaknesses can be seen in multiple areas, such as its generally disappointing historical performance in the stock itself, poor profit margins and generally high debt management risk. Get the full

Summit Materials Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

KLX (KLXI) - FREE Research Report

Weise Theodore L, who is Director at KLX, bought 2,000 shares at $30.43 on May 25, 2016. Following this transaction, the Director owned 6,895 shares meaning that the stake was boosted by 40.86% with the 2,000-share transaction.

The shares most recently traded at $33.27, up $2.84, or 8.54% since the insider transaction. Historical insider transactions for KLX go as follows:

  • 4-Week # shares bought: 5,000
  • 4-Week # shares sold: 405
  • 12-Week # shares bought: 5,000
  • 12-Week # shares sold: 405
  • 24-Week # shares bought: 5,000
  • 24-Week # shares sold: 405

The average volume for KLX has been 438,300 shares per day over the past 30 days. KLX has a market cap of $1.7 billion and is part of the industrial goods sector and aerospace/defense industry. Shares are up 7.28% year-to-date as of the close of trading on Wednesday.

KLX Inc., together with its subsidiaries, distributes aerospace fasteners and consumables, and provides logistics services for the commercial, business jet, and military markets worldwide. It operates in two segments, Aerospace Solutions Group (ASG) and Energy Services Group (ESG). The company has a P/E ratio of 14.7. Currently, there are 2 analysts who rate KLX a buy, no analysts rate it a sell, and 6 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on KLXI - FREE

TheStreet Quant Ratings

rates KLX as a

hold

. Among the primary strengths of the company is its respectable return on equity which we feel is likely to continue. At the same time, however, we also find weaknesses including deteriorating net income, poor profit margins and weak operating cash flow. Get the full

KLX Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Biomarin Pharmaceutical (BMRN) - FREE Research Report

Spiegelman Daniel K, who is EVP, Chief Financial Officer at Biomarin Pharmaceutical, sold 3,769 shares at $87.07 on May 25, 2016. Following this transaction, the EVP, Chief Financial Officer owned 58,644 shares meaning that the stake was reduced by 6.04% with the 3,769-share transaction.

The shares most recently traded at $86.43, down $0.64, or 0.75% since the insider transaction. Historical insider transactions for Biomarin Pharmaceutical go as follows:

  • 4-Week # shares sold: 19,658
  • 12-Week # shares sold: 22,909
  • 24-Week # shares sold: 38,894

The average volume for Biomarin Pharmaceutical has been 1.6 million shares per day over the past 30 days. Biomarin Pharmaceutical has a market cap of $14.3 billion and is part of the health care sector and drugs industry. Shares are down 15.23% year-to-date as of the close of trading on Wednesday.

BioMarin Pharmaceutical Inc. develops and commercializes pharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. Currently, there are 14 analysts who rate Biomarin Pharmaceutical a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on BMRN - FREE

TheStreet Quant Ratings

rates Biomarin Pharmaceutical as a

sell

. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, disappointing return on equity, weak operating cash flow and generally disappointing historical performance in the stock itself. Get the full

Biomarin Pharmaceutical Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.